Company and Partner News
2024 Letter to Shareholders
We made good progress over the course of 2023 towards advancing the company’s differentiated royalty business model. As is the case with any emerging biotech portfolio, there were both positive and negative developments, although many of our key near-term drivers of value remain intact.
XOMA raises up to $140M with Blue Owl Capital
“The Blue Owl financing provides us with significant non-dilutive capital to drive shareholder value through stock repurchases and additional royalty and milestone acquisitions,” stated Brad Sitko, Chief Investment Officer of XOMA.
2023 Letter to Shareholders
Since joining the Company in January 2023 as Executive Chairman and interim CEO, I have come to better appreciate the opportunity presented by XOMA’s unique business model and seasoned team, and equally important, the optionality embedded within our growing royalty and milestone portfolio.
Press Releases
- XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
- XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
- Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
